-
1
-
-
34248136828
-
Inflammatory bowel disease: cause and immunobiology
-
DOI 10.1016/S0140-6736(07)60750-8, PII S0140673607607508
-
Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology. Lancet 2007;369:1627-40. (Pubitemid 46722636)
-
(2007)
Lancet
, vol.369
, Issue.9573
, pp. 1627-1640
-
-
Baumgart, D.C.1
Carding, S.R.2
-
2
-
-
77955708883
-
New pathophysiological insights and modern treatment of IBD
-
Engel MA, Neurath MF. New pathophysiological insights and modern treatment of IBD. J Gastroenterol 2010;45:571-83.
-
(2010)
J Gastroenterol
, vol.45
, pp. 571-583
-
-
Engel, M.A.1
Neurath, M.F.2
-
3
-
-
79953786419
-
Loss of response and need for adalimumab dose intensification in Crohn's disease: A systematic review
-
Billioud V, Sandborn WJ, Peyrin-Biroulet L. Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review. Am J Gastroenterol 2011;106:674-84.
-
(2011)
Am J Gastroenterol
, vol.106
, pp. 674-684
-
-
Billioud, V.1
Sandborn, W.J.2
Peyrin-Biroulet, L.3
-
4
-
-
62049083383
-
Loss of response and requirement of infliximab dose intensification in Crohn's disease: A review
-
Gisbert JP, Panes J. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. Am J Gastroenterol 2009;104:760-7.
-
(2009)
Am J Gastroenterol
, vol.104
, pp. 760-767
-
-
Gisbert, J.P.1
Panes, J.2
-
5
-
-
79952788410
-
Review article: Remission rates achievable by current therapies for inflammatory bowel disease
-
Peyrin-Biroulet L, Lemann M. Review article: remission rates achievable by current therapies for inflammatory bowel disease. Aliment Pharmacol Ther 2011;33:870-9.
-
(2011)
Aliment Pharmacol Ther
, vol.33
, pp. 870-879
-
-
Peyrin-Biroulet, L.1
Lemann, M.2
-
6
-
-
33344466383
-
Defective acute inflammation in Crohn's disease: A clinical investigation
-
DOI 10.1016/S0140-6736(06)68265-2, PII S0140673606682652
-
Marks DJ, Harbord MW, MacAllister R, et al. Defective acute inflammation in Crohn's disease: a clinical investigation. Lancet 2006;367:668-78. (Pubitemid 43289157)
-
(2006)
Lancet
, vol.367
, Issue.9511
, pp. 668-678
-
-
Marks, D.J.1
Harbord, M.W.2
MacAllister, R.3
Rahman, F.Z.4
Young, J.5
Al-Lazikani, B.6
Lees, W.7
Novelli, M.8
Bloom, S.9
Segal, A.W.10
-
7
-
-
69449105914
-
Disordered macrophage cytokine secretion underlies impaired acute inflammation and bacterial clearance in Crohn's disease
-
Smith AM, Rahman FZ, Hayee B, et al. Disordered macrophage cytokine secretion underlies impaired acute inflammation and bacterial clearance in Crohn's disease. J Exp Med 2009;206:1883-97.
-
(2009)
J Exp Med
, vol.206
, pp. 1883-1897
-
-
Smith, A.M.1
Rahman, F.Z.2
Hayee, B.3
-
8
-
-
46149125761
-
Crohn's disease: beyond antagonists of tumour necrosis factor
-
DOI 10.1016/S0140-6736(08)60995-2, PII S0140673608609952
-
Peyrin-Biroulet L, Desreumaux P, Sandborn WJ, et al. Crohn's disease: beyond antagonists of tumour necrosis factor. Lancet 2008;372:67-81. (Pubitemid 351902263)
-
(2008)
The Lancet
, vol.372
, Issue.9632
, pp. 67-81
-
-
Peyrin-Biroulet, L.1
Desreumaux, P.2
Sandborn, W.J.3
Colombel, J.-F.4
-
9
-
-
29744450121
-
Both IL-12p70 and IL-23 are synthesized during active Crohn's disease and are down-regulated by treatment with anti-IL-12 p40 monoclonal antibody
-
DOI 10.1097/01.MIB.0000194183.92671.b6
-
Fuss IJ, Becker C, Yang Z, et al. Both IL-12p70 and IL-23 are synthesized during active Crohn's disease and are down-regulated by treatment with anti-IL-12p40 monoclonal antibody. Inflamm Bowel Dis 2006;12:9-15. (Pubitemid 43032445)
-
(2006)
Inflammatory Bowel Diseases
, vol.12
, Issue.1
, pp. 9-15
-
-
Fuss, I.J.1
Becker, C.2
Yang, Z.3
Groden, C.4
Hornung, R.L.5
Heller, F.6
Neurath, M.F.7
Strober, W.8
Mannon, P.J.9
-
10
-
-
33847206969
-
IL-17 family cytokines and the expanding diversity of effector T cell lineages
-
DOI 10.1146/annurev.immunol.25.022106.141557
-
Weaver CT, Hatton RD, Mangan PR, et al. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol 2007;25:821-52. (Pubitemid 46697925)
-
(2007)
Annual Review of Immunology
, vol.25
, pp. 821-852
-
-
Weaver, C.T.1
Hatton, R.D.2
Mangan, P.R.3
Harrington, L.E.4
-
11
-
-
33646804892
-
Critical role of IL-17 receptor signalling in acute TNBS-induced colitis
-
Zhang Z, Zheng M, Bindas J, et al. Critical role of IL-17 receptor signalling in acute TNBS-induced colitis. Inflamm Bowel Dis 2006;12:382-8.
-
(2006)
Inflamm Bowel Dis
, vol.12
, pp. 382-388
-
-
Zhang, Z.1
Zheng, M.2
Bindas, J.3
-
12
-
-
79955551587
-
Regulation of homeostasis and inflammation in the intestine
-
MacDonald TT, Monteleone I, Fantini MC, et al. Regulation of homeostasis and inflammation in the intestine. Gastroenterology 2011;140:1768-75.
-
(2011)
Gastroenterology
, vol.140
, pp. 1768-1775
-
-
MacDonald, T.T.1
Monteleone, I.2
Fantini, M.C.3
-
13
-
-
85047690640
-
Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis
-
DOI 10.1172/JCI200419836
-
Fuss IJ, Heller F, Boirivant M, et al. Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize and atypical Th2 response in ulcerative colitis. J Clin Invest 2004;113:1490-7. (Pubitemid 39071705)
-
(2004)
Journal of Clinical Investigation
, vol.113
, Issue.10
, pp. 1490-1497
-
-
Fuss, I.J.1
Heller, F.2
Boirivant, M.3
Leon, F.4
Yoshida, M.5
Fichtner-Feigl, S.6
Yang, Z.7
Exley, M.8
Kitani, A.9
Blumberg, R.S.10
Mannon, P.11
Strober, W.12
-
14
-
-
0036107919
-
Immunoregulation in the gut: Success and failures in human disease
-
Monteleone I, Vavassori P, Biancone L, et al. Immunoregulation in the gut: success and failures in human disease. Gut 2002;50: iii60-4. (Pubitemid 34407458)
-
(2002)
Gut
, vol.50
, Issue.SUPPL. 3
-
-
Monteleone, I.1
Vavassori, P.2
Biancone, L.3
Monteleone, G.4
Pallone, F.5
-
15
-
-
80955178844
-
Surgery for adult Crohn's disease: What is the actual risk?
-
Bouguen G, Peyrin-Biroulet L. Surgery for adult Crohn's disease: what is the actual risk? Gut 2011;60:1178-81.
-
(2011)
Gut
, vol.60
, pp. 1178-1181
-
-
Bouguen, G.1
Peyrin-Biroulet, L.2
-
16
-
-
79952582391
-
Kinoid of human tumor necrosis factor-alpha for rheumatoid arthritis
-
Semerano L, Assier E, Delavallee L, et al. Kinoid of human tumor necrosis factor-alpha for rheumatoid arthritis. Expert Opin Biol Ther 2011;11:545-50.
-
(2011)
Expert Opin Biol Ther
, vol.11
, pp. 545-550
-
-
Semerano, L.1
Assier, E.2
Delavallee, L.3
-
17
-
-
77952514447
-
Active immunization to tumor necrosis factor-alpha is effective in treating chronic established inflammatory disease: A long-term study in a transgenic model of arthritis
-
Delavallee L, Semerano L, Assier E, et al. Active immunization to tumor necrosis factor-alpha is effective in treating chronic established inflammatory disease: a long-term study in a transgenic model of arthritis. Arthritis Res Ther 2009;11:R195.
-
(2009)
Arthritis Res Ther
, vol.11
-
-
Delavallee, L.1
Semerano, L.2
Assier, E.3
-
18
-
-
33845879373
-
TNFalpha kinoid vaccination-induced neutralizing antibodies to TNFalpha protect mice from autologous TNFalpha-driven chronic and acute inflammation
-
DOI 10.1073/pnas.0604827103
-
Le Buanec H, Delavallee L, Bessis N, et al. TNFalpha kinoid vaccination-induced neutralizing antibodies to TNFalpha protect mice from autologous TNFalpha-driven chronic and acute inflammation. Proc Natl Acad Sci U S A 2006;103:19442-7. (Pubitemid 46026050)
-
(2006)
Proceedings of the National Academy of Sciences of the United States of America
, vol.103
, Issue.51
, pp. 19442-19447
-
-
Le, B.H.1
Delavallee, L.2
Bessis, N.3
Paturance, S.4
Bizzini, B.5
Gallo, R.6
Zagury, D.7
Boissier, M.-C.8
-
20
-
-
84860583009
-
Active therapeutic immunization against TNF with a TNF-kinoid in Crohn's disease patients: A phase 1-2 study
-
Rogler G, Michetti PF, Kruger FC, et al. Active therapeutic immunization against TNF with a TNF-kinoid in Crohn's disease patients: a phase 1-2 study. Digestive Disease Week 2010;140: T1234.
-
(2010)
Digestive Disease Week
, vol.140
-
-
Rogler, G.1
Michetti, P.F.2
Kruger, F.C.3
-
21
-
-
33745553245
-
A phase 1/2A trial of STA 5326, an oral interleukin-12/23 inhibitor, in patients with active moderate to severe Crohn's disease
-
DOI 10.1097/01.ibd.0000225337.14356.31, PII 0005472520060700000004
-
Burakoff R, Barish CF, Riff D, et al. A phase 1/2A trial of STA 5326, an oral interleukin-12/23 inhibitor, in patients with active moderate to severe Crohn's disease. Inflamm Bowel Dis 2006;12:558-65. (Pubitemid 43977736)
-
(2006)
Inflammatory Bowel Diseases
, vol.12
, Issue.7
, pp. 558-565
-
-
Burakoff, R.1
Barish, C.F.2
Riff, D.3
Pruitt, R.4
Chey, W.Y.5
Farraye, F.A.6
Shafran, I.7
Katz, S.8
Krone, C.L.9
Vander, V.M.10
Stevens, C.11
Sherman, M.L.12
Jacobson, E.13
Bleday, R.14
-
22
-
-
77953693548
-
Randomized, double-blind, placebo-controlled trial of the oral interleukin-12/23 inhibitor apilimod mesylate for treatment of active Crohn's disease
-
Sands BE, Jacobson EW, Sylwestrowicz T, et al. Randomized, double-blind, placebo-controlled trial of the oral interleukin-12/23 inhibitor apilimod mesylate for treatment of active Crohn's disease. Inflamm Bowel Dis 2010;16:1209-18.
-
(2010)
Inflamm Bowel Dis
, vol.16
, pp. 1209-1218
-
-
Sands, B.E.1
Jacobson, E.W.2
Sylwestrowicz, T.3
-
23
-
-
53049091561
-
A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease
-
Sandborn WJ, Feagan BG, Fedorak RN, et al. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology 2008;35:1130-41.
-
(2008)
Gastroenterology
, vol.35
, pp. 1130-1141
-
-
Sandborn, W.J.1
Feagan, B.G.2
Fedorak, R.N.3
-
24
-
-
72049124819
-
Relationship of C-reactive protein with clinical response after therapy with ustekinumab in Crohn's disease
-
Toedter GP, Blank M, Lang Y, et al. Relationship of C-reactive protein with clinical response after therapy with ustekinumab in Crohn's disease. Am J Gastroenterol 2009;104:2768-73.
-
(2009)
Am J Gastroenterol
, vol.104
, pp. 2768-2773
-
-
Toedter, G.P.1
Blank, M.2
Lang, Y.3
-
25
-
-
81255206921
-
A multicenter, randomized, double-blind, placebo-controlled phase 2b study of ustekinumab, a human monoclonal antibody to IL-12/23p40, in patients with moderately to severly active Crohn's disease: Results through week 22 from the Certifi trial
-
Sandborn WJ, Gasink C, Gao LL, et al. A multicenter, randomized, double-blind, placebo-controlled phase 2b study of ustekinumab, a human monoclonal antibody to IL-12/23p40, in patients with moderately to severly active Crohn's disease: results through week 22 from the Certifi trial. Digestive Disease Week 2011;140:A592.
-
(2011)
Digestive Disease Week
, vol.140
-
-
Sandborn, W.J.1
Gasink, C.2
Gao, L.L.3
-
26
-
-
8344284998
-
Anti-interleukin-12 antibody for active Crohn's disease
-
DOI 10.1056/NEJMoa033402
-
Mannon PJ, Fuss IJ, Mayer L, et al. Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med 2004;351:2069-79. (Pubitemid 39482500)
-
(2004)
New England Journal of Medicine
, vol.351
, Issue.20
, pp. 2069-2079
-
-
Mannon, P.J.1
Fuss, I.J.2
Mayer, L.3
Elson, C.O.4
Sandborn, W.J.5
Present, D.6
Dolin, B.7
Goodman, N.8
Groden, C.9
Hornung, R.L.10
Quezado, M.11
Neurath, M.F.12
Salfeld, J.13
Veldman, G.M.14
Schwertschlag, U.15
Strober, W.16
-
28
-
-
84860599482
-
-
US National Institutes of Health. ClinicalTrials.gov [Online] accessed Jul 2011
-
US National Institutes of Health. ClinicalTrials.gov [Online]. 2011. http://www.clinicaltrials.gov (accessed Jul 2011).
-
(2011)
-
-
-
29
-
-
10744232542
-
Basiliximab (anti-CD25) in combination with steroids may be an effective new treatment for steroid-resistant ulcerative colitis
-
Creed TJ, Norman MR, Probert CS, et al. Basiliximab (anti-CD25) in combination with steroids may be an effective new treatment for steroid-resistant ulcerative colitis. Aliment Pharmacol Ther 2003;18:65-75.
-
(2003)
Aliment Pharmacol Ther
, vol.18
, pp. 65-75
-
-
Creed, T.J.1
Norman, M.R.2
Probert, C.S.3
-
30
-
-
33646232018
-
Basiliximab for the treatment of steroid-resistant ulcerative colitis: Further experience in moderate and severe disease
-
Creed TJ, Probert CS, Norman MN, et al. Basiliximab for the treatment of steroid-resistant ulcerative colitis: further experience in moderate and severe disease. Aliment Pharmacol Ther 2006;23:1435-42.
-
(2006)
Aliment Pharmacol Ther
, vol.23
, pp. 1435-1442
-
-
Creed, T.J.1
Probert, C.S.2
Norman, M.N.3
-
31
-
-
0037285975
-
A pilot study on the use of the humanized anti-interleukin-2 receptor antibody daclizumab in active ulcerative colitis
-
DOI 10.1016/S0002-9270(02)05907-5
-
Van Assche G, Dalle I, Noman M, et al. A pilot study on the use of the humanized anti-interleukin-2 receptor antibody daclizumab in ulcerative colitis. Am J Gastroenterol 2003;98:369-76. (Pubitemid 36232388)
-
(2003)
American Journal of Gastroenterology
, vol.98
, Issue.2
, pp. 369-376
-
-
Van Assche, G.1
Dalle, I.2
Noman, M.3
Aerden, I.4
Swijsen, C.5
Asnong, K.6
Maes, B.7
Ceuppens, J.8
Geboes, K.9
Rutgeerts, P.10
-
32
-
-
33750343050
-
Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: A randomised, double blind, placebo controlled, dose ranging trial
-
DOI 10.1136/gut.2005.089854
-
Van Assche G, Sandborn WJ, Feagan BG, et al. Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severly active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial. Gut 2006;55:1568-74. (Pubitemid 44629204)
-
(2006)
Gut
, vol.55
, Issue.11
, pp. 1568-1574
-
-
Van Assche, G.1
Sandborn, W.J.2
Feagan, B.G.3
Salzberg, B.A.4
Silvers, D.5
Monroe, P.S.6
Pandak, W.M.7
Anderson, F.H.8
Valentine, J.F.9
Wild, G.E.10
Geenen, D.J.11
Sprague, R.12
Targan, S.R.13
Rutgeerts, P.14
Vexler, V.15
Young, D.16
Shames, R.S.17
-
33
-
-
33746132472
-
A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease
-
DOI 10.1136/gut.2005.079434
-
Reinisch W, Hommes D, Van Assche G, et al. A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised antiinterferon gamma antibody, in patients with moderate to severe Crohn's disease. Gut 2006;55:1138-44. (Pubitemid 44085682)
-
(2006)
Gut
, vol.55
, Issue.8
, pp. 1138-1144
-
-
Reinisch, W.1
Hommes, D.W.2
Van Assche, G.3
Colombel, J.-F.4
Gendre, J.-P.5
Oldenburg, B.6
Teml, A.7
Geboes, K.8
Ding, H.9
Zhang, L.10
Tang, M.11
Cheng, M.12
Van Deventer, S.J.H.13
Rutgeerts, P.14
Pearce, T.15
-
34
-
-
33746176176
-
Fontolizumab, a humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease
-
DOI 10.1136/gut.2005.079392
-
Hommes DW, Mikhajlova TL, Stoinov S, et al. Fontolizumab, a humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease. Gut 2006;55:1131-7. (Pubitemid 44085681)
-
(2006)
Gut
, vol.55
, Issue.8
, pp. 1131-1137
-
-
Hommes, D.W.1
Mikhajlova, T.L.2
Stoinov, S.3
Stimac, D.4
Vucelic, B.5
Lonovics, J.6
Zakuciova, M.7
D'Haens, G.8
Van Assche, G.9
Ba, S.10
Lee, S.11
Pearce, T.12
-
35
-
-
73949092345
-
Fontolizumab in moderate to severe Crohn's disease: A phase 2, randomized, double-blind, placebo-controlled, multiple-dose study
-
Reinisch W, de Villiers WJ, Bene L, et al. Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study. Inflamm Bowel Dis 2010;16:233-42.
-
(2010)
Inflamm Bowel Dis
, vol.16
, pp. 233-242
-
-
Reinisch, W.1
De Villiers, W.J.2
Bene, L.3
-
36
-
-
34548190038
-
IL-6 signaling in inflammatory bowel disease: Pathophysiological role and clinical relevance
-
DOI 10.1002/ibd.20148
-
Mudter J, Neurath MF. IL-6 signaling in inflammatory bowel disease: pathophysiological role and clinical relevance. Inflamm Bowel Dis 2007;13:1016-23. (Pubitemid 47309974)
-
(2007)
Inflammatory Bowel Diseases
, vol.13
, Issue.8
, pp. 1016-1023
-
-
Mudter, J.1
Neurath, M.F.2
-
37
-
-
76149132672
-
Early-onset Crohn disease is associated with male sex and a polymorphism in the IL-6 promoter
-
Sagiv-Friedgut K, Karban A, Weiss B, et al. Early-onset Crohn disease is associated with male sex and a polymorphism in the IL-6 promoter. J Pediatr Gastroenterol Nutr 2010;50:22-6.
-
(2010)
J Pediatr Gastroenterol Nutr
, vol.50
, pp. 22-26
-
-
Sagiv-Friedgut, K.1
Karban, A.2
Weiss, B.3
-
38
-
-
77951188458
-
Upregulation of DNA methyltransferase-mediated gene silencing, anchorageindependent growth, and migration of colon cancer cells by interleukin-6
-
Foran E, Garrity-Park MM, Mureau C, et al. Upregulation of DNA methyltransferase-mediated gene silencing, anchorageindependent growth, and migration of colon cancer cells by interleukin-6. Mol Cancer Res 2010;8:471-81.
-
(2010)
Mol Cancer Res
, vol.8
, pp. 471-481
-
-
Foran, E.1
Garrity-Park, M.M.2
Mureau, C.3
-
39
-
-
77149155643
-
Disease-related expression of the IL6/STAT3/SOCS3 signalling pathway in ulcerative colitis and ulcerative colitis-related carcinogenesis
-
Li Y, de Haar C, Chen M, et al. Disease-related expression of the IL6/STAT3/SOCS3 signalling pathway in ulcerative colitis and ulcerative colitis-related carcinogenesis. Gut 2010;59:227-35.
-
(2010)
Gut
, vol.59
, pp. 227-235
-
-
Li, Y.1
De Haar, C.2
Chen, M.3
-
40
-
-
77949326158
-
Essential roles of IL-6 trans-signaling in colonic epithelial cells, induced by the IL-6/soluble-IL-6 receptor derived from lamina propria macrophages,on the development of colitis-associated premalignant cancer in a murine model
-
Matsumoto S, Hara T, Mitsuyama K, et al. Essential roles of IL-6 trans-signaling in colonic epithelial cells, induced by the IL-6/soluble-IL-6 receptor derived from lamina propria macrophages,on the development of colitis-associated premalignant cancer in a murine model. J Immunol 2010;184:1543-51.
-
(2010)
J Immunol
, vol.184
, pp. 1543-1551
-
-
Matsumoto, S.1
Hara, T.2
Mitsuyama, K.3
-
41
-
-
79960182099
-
Pharmacokinetics, pharmacodynamics, and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-in-human study
-
Xu Y, Bouman-Thio E, Comisar C, et al. Pharmacokinetics, pharmacodynamics, and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-in-human study. Br J Clin Pharmacol 2011;72:270-81.
-
(2011)
Br J Clin Pharmacol
, vol.72
, pp. 270-281
-
-
Xu, Y.1
Bouman-Thio, E.2
Comisar, C.3
-
42
-
-
77956646068
-
Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: Meta-analysis of six initial trials and five long-term extensions
-
Nishimoto N, Ito K, Takagi N. Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long-term extensions. Mod Rheumatol 2010;20:222-32.
-
(2010)
Mod Rheumatol
, vol.20
, pp. 222-232
-
-
Nishimoto, N.1
Ito, K.2
Takagi, N.3
-
43
-
-
73449118587
-
Comparison of tociliziumab monotherapy versus methotrexate monotherapy in patients with moderate to sever rheumatoid arthritis: The AMBITION study
-
Jones G, Sebba A, Gu J, et al. Comparison of tociliziumab monotherapy versus methotrexate monotherapy in patients with moderate to sever rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 2010;69:88-96.
-
(2010)
Ann Rheum Dis
, vol.69
, pp. 88-96
-
-
Jones, G.1
Sebba, A.2
Gu, J.3
-
44
-
-
77958521437
-
-
accessed Jul 2011
-
US Food and Drug Administration. FDA Approves New Drug for Rheumatoid Arthritis. 2010. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ ucm197108.htm (accessed Jul 2011).
-
(2010)
FDA Approves New Drug for Rheumatoid Arthritis
-
-
-
45
-
-
11144358366
-
A Pilot Randomized Trial of a Human Anti-Interleukin-6 Receptor Monoclonal Antibody in Active Crohn's Disease
-
DOI 10.1053/j.gastro.2004.01.012
-
Ito H, Takazoe M, Fukuda Y, et al. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology 2004;126:989-96. (Pubitemid 38451170)
-
(2004)
Gastroenterology
, vol.126
, Issue.4
, pp. 989-996
-
-
Ito, H.1
Takazoe, M.2
Fukuda, Y.3
Hibi, T.4
Kusugami, K.5
Andoh, A.6
Matsumoto, T.7
Yamamura, T.8
Azuma, J.9
Nishimoto, N.10
Yoshizaki, K.11
Shimoyama, T.12
Kishimoto, T.13
-
46
-
-
23244455992
-
Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution
-
DOI 10.1016/j.gastro.2005.05.002, PII S0016508505008723
-
Heller F, Florian P, Bojarski C, et al. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology 2005;129:550-64. (Pubitemid 41096643)
-
(2005)
Gastroenterology
, vol.129
, Issue.2
, pp. 550-564
-
-
Heller, F.1
Florian, P.2
Bojarski, C.3
Richter, J.4
Christ, M.5
Hillenbrand, B.6
Mankertz, J.7
Gitter, A.H.8
Burgel, N.9
Fromm, M.10
Zeitz, M.11
Fuss, I.12
Strober, W.13
Schulzke, J.D.14
-
47
-
-
79952445609
-
IBD: Of mice and men - Shedding new light on IL-13 activity in IBD
-
Danese S. IBD: of mice and men - shedding new light on IL-13 activity in IBD. Nat Rev Gastroenterol Hepatol 2011;8:128-9.
-
(2011)
Nat Rev Gastroenterol Hepatol
, vol.8
, pp. 128-129
-
-
Danese, S.1
-
48
-
-
79952532799
-
Suppression of inflammation in ulcerative colitis by interferon-b-1a is accompanied by inhibition of IL-13 production
-
Mannon PJ, Hornung RL, Yang Z, et al. Suppression of inflammation in ulcerative colitis by interferon-b-1a is accompanied by inhibition of IL-13 production. Gut 2011;60:449-55.
-
(2011)
Gut
, vol.60
, pp. 449-455
-
-
Mannon, P.J.1
Hornung, R.L.2
Yang, Z.3
-
49
-
-
78649829431
-
Colitis and intestinal inflammation in IL10-/- mice results from IL-13Ra2-mediated attenuation of IL-13 activity
-
Wilson MS, Ramalingam TR, Rivollier A, et al. Colitis and intestinal inflammation in IL10-/- mice results from IL-13Ra2-mediated attenuation of IL-13 activity. Gastroenterology 2011;140:254-64.
-
(2011)
Gastroenterology
, vol.140
, pp. 254-264
-
-
Wilson, M.S.1
Ramalingam, T.R.2
Rivollier, A.3
-
50
-
-
66149159613
-
IL-21 enhances NK cell activation and cytolytic activity and induces Th17 cell differentiation in inflammatory bowel disease
-
Liu Z, Yang L, Cui Y, et al. IL-21 enhances NK cell activation and cytolytic activity and induces Th17 cell differentiation in inflammatory bowel disease. Inflamm Bowel Dis 2009;15:1133-44.
-
(2009)
Inflamm Bowel Dis
, vol.15
, pp. 1133-1144
-
-
Liu, Z.1
Yang, L.2
Cui, Y.3
-
52
-
-
79952435375
-
Interleukins IL-33 and IL-17/IL-17A in patients with ulcerative colitis
-
Ajdukovic J, Tonkic A, Salamunic I, et al. Interleukins IL-33 and IL-17/IL-17A in patients with ulcerative colitis. Hepatogastroenterology 2010;57:1442-4.
-
(2010)
Hepatogastroenterology
, vol.57
, pp. 1442-1444
-
-
Ajdukovic, J.1
Tonkic, A.2
Salamunic, I.3
-
53
-
-
72549107316
-
Differential regulation of interleukin 17 and interferon gamma production in inflammatory bowel disease
-
Rovedatti L, Kudo T, Biancheri P, et al. Differential regulation of interleukin 17 and interferon gamma production in inflammatory bowel disease. Gut 2009;58:1629-36.
-
(2009)
Gut
, vol.58
, pp. 1629-1636
-
-
Rovedatti, L.1
Kudo, T.2
Biancheri, P.3
-
54
-
-
16444368855
-
Elevated systemic levels of free interleukin-18 (IL-18) in patients with Crohn's disease
-
Ludwiczek O, Kaser A, Novick D, et al. Elevated systemic levels of free interleukin-18 (IL-18) in patients with Crohn's disease. Eur Cytokine Netw 2005;16:27-33. (Pubitemid 40478073)
-
(2005)
European Cytokine Network
, vol.16
, Issue.1
, pp. 27-33
-
-
Ludwiczek, O.1
Kaser, A.2
Novick, D.3
Dinarello, C.A.4
Rubinstein, M.5
Tilg, H.6
-
55
-
-
34547557700
-
Interleukin-18 and its binding protein in patients with inflammatory bowel disease during remission and exacerbation
-
Naftali T, Novick D, Gabay G, et al. Interleukin-18 and its binding protein in patients with inflammatory bowel disease during remission and exacerbation. Isr Med Assoc J 2007;9:504-8. (Pubitemid 47193376)
-
(2007)
Israel Medical Association Journal
, vol.9
, Issue.7
, pp. 504-508
-
-
Naftali, T.1
Novick, D.2
Gabay, G.3
Rubinstein, M.4
Novis, B.5
-
57
-
-
80052100689
-
T cell responses: Anger management for TH17 cells
-
Bordon Y. T cell responses: anger management for TH17 cells. Nat Rev Immunol 2011;11:567-632.
-
(2011)
Nat Rev Immunol
, vol.11
, pp. 567-632
-
-
Bordon, Y.1
-
58
-
-
84860582481
-
Efficacy, safety and tolerability of vidofludimus in patients with inflammatory bowel disease: The ENTRANCE study
-
Stockholm, September 25-26th 2011, European Cancer Organisation
-
Herrlinger KR, Diculescu M, Fellermann K, et al. Efficacy, safety and tolerability of vidofludimus in patients with inflammatory bowel disease: the ENTRANCE study. 6th Congress of ECCO 2011:P209. Stockholm, September 25-26th 2011, European Cancer Organisation.
-
6th Congress of ECCO 2011
, pp. 209
-
-
Herrlinger, K.R.1
Diculescu, M.2
Fellermann, K.3
-
60
-
-
78650362917
-
Discovery of CP-690,550: A potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection
-
Flanagan ME, Blumenkopf TA, Brissette WH, et al. Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection. J Med Chem 2010;53:8468-84.
-
(2010)
J Med Chem
, vol.53
, pp. 8468-8484
-
-
Flanagan, M.E.1
Blumenkopf, T.A.2
Brissette, W.H.3
-
61
-
-
79955027327
-
Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550)
-
Ghoreschi K, Jesson MI, Lee JL, et al. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol 2011;186:4234-43.
-
(2011)
J Immunol
, vol.186
, pp. 4234-4243
-
-
Ghoreschi, K.1
Jesson, M.I.2
Lee, J.L.3
-
62
-
-
84859050689
-
Phase 2 randomized study of CP-690,550, an oral janus kinase inhibitor, in active Crohn's disease
-
Sandborn WJ, Ghosh S, Panes J, et al. Phase 2 randomized study of CP-690,550, an oral janus kinase inhibitor, in active Crohn's disease. Digestive Disease Week 2011;140:A745.
-
(2011)
Digestive Disease Week
, vol.140
-
-
Sandborn, W.J.1
Ghosh, S.2
Panes, J.3
-
63
-
-
84859050689
-
Phase 2 study of CP- 690,550, and oral janus kinase inhibitor, in active ulcerative colitis
-
Sandborn WJ, Ghosh S, Panes J, et al. Phase 2 study of CP- 690,550, and oral janus kinase inhibitor, in active ulcerative colitis. Digestive Disease Week 2011;140:A594.
-
(2011)
Digestive Disease Week
, vol.140
-
-
Sandborn, W.J.1
Ghosh, S.2
Panes, J.3
-
64
-
-
0029813545
-
+ Th1-like responses
-
Berg DJ, Davidson N, Kuhn R, et al. Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses. J Clin Invest 1996;98:1010-20. (Pubitemid 26293320)
-
(1996)
Journal of Clinical Investigation
, vol.98
, Issue.4
, pp. 1010-1020
-
-
Berg, D.J.1
Davidson, N.2
Kuhn, R.3
Muller, W.4
Menon, S.5
Holland, G.6
Thompson-Snipes, L.7
Leach, M.W.8
Rennick, D.9
-
65
-
-
0031903013
-
Increased secretion of pro-inflammatory cytokines by circulating polymorphonuclear neutrophils and regulation by interleukin 10 during intestinal inflammation
-
Nikolaus S, Bauditz J, Gionchetti P, et al. Increased secretion of pro-inflammatory cytokines by circulating polymorphonuclear neutrophils and regulation by interleukin 10 during intestinal inflammation. Gut 1998;42:470-6. (Pubitemid 28186561)
-
(1998)
Gut
, vol.42
, Issue.4
, pp. 470-476
-
-
Nikolaus, S.1
Bauditz, J.2
Gionchetti, P.3
Witt, C.4
Lochs, H.5
Schreiber, S.6
-
66
-
-
55049111426
-
Sequence variants in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility
-
Franke A, Balschun T, Karlsen TH, et al. Sequence variants in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility. Nat Genet 2008;40:1319-23.
-
(2008)
Nat Genet
, vol.40
, pp. 1319-1323
-
-
Franke, A.1
Balschun, T.2
Karlsen, T.H.3
-
67
-
-
0030835754
-
Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease
-
DOI 10.1053/gast.1997.v113.pm9247454
-
van Deventer SJ, Elson CO, Fedorak R. Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Crohn's Disease Study Group. Gastroenterology 1997;113:383-9. (Pubitemid 27351761)
-
(1997)
Gastroenterology
, vol.113
, Issue.2
, pp. 383-389
-
-
Van Deventer, S.J.H.1
Elson, C.O.2
Fedorak, R.N.3
-
68
-
-
0034463305
-
Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease
-
Fedorak RN, Gangl A, Elson CO, et al. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. Gastroenterology 2000;119:1473-82. (Pubitemid 32198672)
-
(2000)
Gastroenterology
, vol.119
, Issue.6
, pp. 1473-1482
-
-
Fedorak, R.N.1
Gangl, A.2
Elson, C.O.3
Rutgeerts, P.4
Schreiber, S.5
Wild, G.6
Hanauer, S.B.7
Kilian, A.8
Cohard, M.9
LeBeaut, A.10
Feagan, B.11
-
69
-
-
0034464148
-
Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease
-
Schreiber S, Fedorak RN, Nielsen OH, et al. Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group. Gastroenterology 2000;119:1461-72. (Pubitemid 32198671)
-
(2000)
Gastroenterology
, vol.119
, Issue.6
, pp. 1461-1472
-
-
Schreiber, S.1
Fedorak, R.N.2
Nielsen, O.H.3
Wild, G.4
Williams, C.N.5
Nikolaus, S.6
Jacyna, M.7
Lashner, B.A.8
Gangl, A.9
Rutgeerts, P.10
Isaacs, K.11
Van Deventer, S.J.H.12
Koningsberger, J.C.13
Cohard, M.14
LeBeaut, A.15
Hanauer, S.B.16
-
70
-
-
0034956334
-
Interleukin 10 (Tenovil) in the prevention of postoperative recurrence of Crohn's disease
-
DOI 10.1136/gut.49.1.42
-
Colombel JF, Rutgeerts P, Malchow HA, et al. Interleukin 10 (Tenovil) in the prevention of postoperative recurrence of Crohn's disease. Gut 2001;49:42-6. (Pubitemid 32601878)
-
(2001)
Gut
, vol.49
, Issue.1
, pp. 42-46
-
-
Colombel, J.-F.1
Rutgeerts, P.2
Malchow, H.3
Jacyna, M.4
Nielsen, O.H.5
Rask-Madsen, J.6
Van Deventer, S.7
Ferguson, A.8
Desreumaux, P.9
Forbes, A.10
Geboes, K.11
Melani, L.12
Cohard, M.13
-
71
-
-
33744933432
-
A Phase I Trial With Transgenic Bacteria Expressing Interleukin-10 in Crohn's Disease
-
DOI 10.1016/j.cgh.2006.03.028, PII S1542356506003314
-
Braat H, Rottiers P, Hommes DW, et al. A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. Clin Gastroenterol Hepatol 2006;4:754-9. (Pubitemid 43841860)
-
(2006)
Clinical Gastroenterology and Hepatology
, vol.4
, Issue.6
, pp. 754-759
-
-
Braat, H.1
Rottiers, P.2
Hommes, D.W.3
Huyghebaert, N.4
Remaut, E.5
Remon, J.6
Van Deventer, S.J.H.7
Neirynck, S.8
Peppelenbosch, M.P.9
Steidler, L.10
-
72
-
-
0032989443
-
Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn's disease
-
DOI 10.1016/S0016-5085(99)70550-0
-
Sands BE, Bank S, Sninsky CA, et al. Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn's disease. Gastroenterology 1999;117:58-64. (Pubitemid 29297620)
-
(1999)
Gastroenterology
, vol.117
, Issue.1
, pp. 58-64
-
-
Sands, B.E.1
Bank, S.2
Sninsky, C.A.3
Robinson, M.4
Katz, S.5
Singleton, J.W.6
Miner Jr., P.B.7
Safdi, M.A.8
Galandiuk, S.9
Hanauer, S.B.10
Varilek, G.W.11
Buchman, A.L.12
Rodgers, V.D.13
Salzberg, B.14
Cai, B.15
Loewy, J.16
Debruin, M.F.17
Rogge, H.18
Shapiro, M.19
Schwertschlag, U.S.20
more..
-
73
-
-
0036186051
-
Randomized, controlled trial of recombinant human interleukin-11 in patients with active Crohn's disease
-
DOI 10.1046/j.1365-2036.2002.01179.x
-
Sands BE, Winston BD, Salzberg BA, et al. Randomized, controlled trial of recombinant human interleukin-11 in patients with active Crohn's disease. Aliment Pharmacol Ther 2002;16:399-406. (Pubitemid 34214518)
-
(2002)
Alimentary Pharmacology and Therapeutics
, vol.16
, Issue.3
, pp. 399-406
-
-
Sands, B.E.1
Winston, B.D.2
Salzberg, B.3
Safdi, M.4
Barish, C.5
Wruble, L.6
Wilkins, R.7
Shapiro, M.8
Schwertschlag, U.S.9
-
74
-
-
33645455612
-
Randomized, double blind controlled trial of subcutaneous recombinant human interleukin-11 versus prednisolone in active Crohn's disease
-
Herrlinger KR, Witthoeft T, Raedler A, et al. Randomized, double blind controlled trial of subcutaneous recombinant human interleukin-11 versus prednisolone in active Crohn's disease. Am J Gastroenterol 2006;101:793-7.
-
(2006)
Am J Gastroenterol
, vol.101
, pp. 793-797
-
-
Herrlinger, K.R.1
Witthoeft, T.2
Raedler, A.3
-
75
-
-
0036024194
-
Induction and maintenance of clinical remission by interferon-beta in patients wih steroidrefractory active ulcerative colitis-an open long-term pilot trial
-
Musch E, Andus T, Malek M. Induction and maintenance of clinical remission by interferon-beta in patients wih steroidrefractory active ulcerative colitis-an open long-term pilot trial. Aliment Pharmacol Ther 2002;17:1233-9.
-
(2002)
Aliment Pharmacol Ther
, vol.17
, pp. 1233-1239
-
-
Musch, E.1
Andus, T.2
Malek, M.3
-
76
-
-
0042386679
-
Interferon beta-1a in ulcerative colitis: A placebo controlled, randomised, dose escalating study
-
DOI 10.1136/gut.52.9.1286
-
Nikolaus S, Rutgeerts P, Fedorak R, et al. Interferon beta-1a in ulcerative colitis: a placebo controlled, randomised, dose escalating study. Gut 2003;52:1286-90. (Pubitemid 37026460)
-
(2003)
Gut
, vol.52
, Issue.9
, pp. 1286-1290
-
-
Nikolaus, S.1
Rutgeerts, P.2
Fedorak, R.3
Steinhart, A.H.4
Wild, G.E.5
Theuer, D.6
Mohrle, J.7
Schreiber, S.8
-
77
-
-
38349057988
-
Successful treatment of steroid refractory active ulcerative colitis with natural interferonbeta e an open long-term trial
-
Musch E, Andus T, Malek M, et al. Successful treatment of steroid refractory active ulcerative colitis with natural interferonbeta e an open long-term trial. Z Gastroenterol 2007;45:1235-40.
-
(2007)
Z Gastroenterol
, vol.45
, pp. 1235-1240
-
-
Musch, E.1
Andus, T.2
Malek, M.3
-
78
-
-
20444499268
-
Interferon-beta-1a for the treatment of steroid-refractory ulcerative colitis: A randomized, double-blind, placebo-controlled trial
-
DOI 10.1016/S1542-3565(05)00208-9, PII S1542356505002089
-
Musch E, Andus T, Kruis W, et al. Interferon-beta-1a for the treatment of steroid-refactory ulcerative colitis: a randomized, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 2005;3:581-6. (Pubitemid 40824751)
-
(2005)
Clinical Gastroenterology and Hepatology
, vol.3
, Issue.6
, pp. 581-586
-
-
Musch, E.1
Andus, T.2
Kruis, W.3
Raedler, A.4
Spehlmann, M.5
Schreiber, S.6
Krakamp, B.7
Malek, M.8
Malchow, H.9
Zavada, F.10
Feurle, G.E.11
-
79
-
-
49849103846
-
Clinical trial: A multicentre, randomized, double-blind, placebo-controlled, dose-finding, phase II study of subcutaneous interferon-beta-1a in moderately active ulcerative colitis
-
Pena Rossi C, Schrieber S, Golubovic G, et al. Clinical trial: a multicentre, randomized, double-blind, placebo-controlled, dose-finding, phase II study of subcutaneous interferon-beta-1a in moderately active ulcerative colitis. Aliment Pharmacol Ther 2008;28:758-67.
-
(2008)
Aliment Pharmacol Ther
, vol.28
, pp. 758-767
-
-
Pena Rossi, C.1
Schrieber, S.2
Golubovic, G.3
-
80
-
-
65149091969
-
Interferon beta- 1a for the maintenance of remission in patients with Crohn's disease: Results of a phase II dose-finding study
-
Pena Rossi C, Hanauer SB, Tomasevic R, et al. Interferon beta- 1a for the maintenance of remission in patients with Crohn's disease: results of a phase II dose-finding study. Gastroenterology 2009;29:22.
-
(2009)
Gastroenterology
, vol.29
, pp. 22
-
-
Pena Rossi, C.1
Hanauer, S.B.2
Tomasevic, R.3
-
81
-
-
34547469463
-
Development of ulcerative colitis in a patient with multiple sclerosis following treatment with interferonbeta 1a
-
Schott E, Paul F, Wuerfel JT, et al. Development of ulcerative colitis in a patient with multiple sclerosis following treatment with interferon beta 1a. World J Gastroenterol 2007;13:3638-40. (Pubitemid 47162275)
-
(2007)
World Journal of Gastroenterology
, vol.13
, Issue.26
, pp. 3638-3640
-
-
Schott, E.1
Paul, F.2
Wuerfel, J.T.3
Zipp, F.4
Rudolph, B.5
Wiedenmann, B.6
Baumgart, D.C.7
-
82
-
-
79951990263
-
Localized delivery of interferon-10 by Lactobacillus exacerbates experimental colitis
-
McFarland AP, Savan R, Wagage S, et al. Localized delivery of interferon-10 by Lactobacillus exacerbates experimental colitis. PLoS One 2011;6:e16967.
-
(2011)
PLoS One
, vol.6
-
-
McFarland, A.P.1
Savan, R.2
Wagage, S.3
-
83
-
-
34047186008
-
T cell costimulation: A rational target in the therapeutic armamentarium for autoimmune diseases and transplantation
-
DOI 10.1146/annurev.med.58.080205.154004
-
Vincenti F, Luggen M. T cell costimulation: a rational target in the therapeutic armamentarium for autoimmune disease and transplantation. Annu Rev Med 2007;58:347-58. (Pubitemid 46706519)
-
(2007)
Annual Review of Medicine
, vol.58
, pp. 347-358
-
-
Vincenti, F.1
Luggen, M.2
-
84
-
-
4344594765
-
A humanised anti-CD3 monoclonal antibody, visiluzumab, for treatment of severe steroid refractory ulcerative colitis: Preliminary results of a phase 1 study
-
abstract
-
Plevy SE, Salzberg BA, Requerio M. A humanised anti-CD3 monoclonal antibody, visiluzumab, for treatment of severe steroid refractory ulcerative colitis: preliminary results of a phase 1 study (abstract). Gastroenterology 2003;126:A75.
-
(2003)
Gastroenterology
, vol.126
-
-
Plevy, S.E.1
Salzberg, B.A.2
Requerio, M.3
-
85
-
-
35648941736
-
A Phase I Study of Visilizumab, a Humanized Anti-CD3 Monoclonal Antibody, in Severe Steroid-Refractory Ulcerative Colitis
-
DOI 10.1053/j.gastro.2007.08.035, PII S0016508507014916
-
Plevy S, Salzberg B, Van Assche G, et al. A phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis. Gastroenterology 2007;133:1414-22. (Pubitemid 350029746)
-
(2007)
Gastroenterology
, vol.133
, Issue.5
, pp. 1414-1422
-
-
Plevy, S.1
Salzberg, B.2
Van Assche, G.3
Regueiro, M.4
Hommes, D.5
Sandborn, W.6
Hanauer, S.7
Targan, S.8
Mayer, L.9
Mahadevan, U.10
Frankel, M.11
Lowder, J.12
-
86
-
-
77949507036
-
Prospective randomized open-label multicenter phase I/II dose escalation trial of visilizumab (HuM291) in severe steroid-refractory ulcerative colitis
-
Baumgart DC, Targan SR, Dignass AU, et al. Prospective randomized open-label multicenter phase I/II dose escalation trial of visilizumab (HuM291) in severe steroid-refractory ulcerative colitis. Inflamm Bowel Dis 2010;16:620-9.
-
(2010)
Inflamm Bowel Dis
, vol.16
, pp. 620-629
-
-
Baumgart, D.C.1
Targan, S.R.2
Dignass, A.U.3
-
87
-
-
78049514932
-
Anti-CD3 antibody visilizumab is not effective in patients with intravenous corticosteroid-refractory ulcerative colitis
-
Sandborn WJ, Colombel J-F, Frankel M, et al. Anti-CD3 antibody visilizumab is not effective in patients with intravenous corticosteroid- refractory ulcerative colitis. Gut 2010;59:1485-92.
-
(2010)
Gut
, vol.59
, pp. 1485-1492
-
-
Sandborn, W.J.1
Colombel, J.-F.2
Frankel, M.3
-
88
-
-
65449120762
-
Transient cytokine-induced liver injury following administration of the humanized anti-CD3 antibody visilizumab (HuM291) in Crohn's disease
-
Baumgart DC, Lowder JN, Targan SR, et al. Transient cytokine-induced liver injury following administration of the humanized anti-CD3 antibody visilizumab (HuM291) in Crohn's disease. Am J Gastroenterol 2009;104:868-76.
-
(2009)
Am J Gastroenterol
, vol.104
, pp. 868-876
-
-
Baumgart, D.C.1
Lowder, J.N.2
Targan, S.R.3
-
89
-
-
80053566144
-
Randomised placebo-controlled trial of rituximab (anti-CD20) in active ulcerative colitis
-
Leiper K, Martin K, Ellis A, et al. Randomised placebo-controlled trial of rituximab (anti-CD20) in active ulcerative colitis. Gut 2011;60:1520-6.
-
(2011)
Gut
, vol.60
, pp. 1520-1526
-
-
Leiper, K.1
Martin, K.2
Ellis, A.3
-
90
-
-
79952078492
-
Rituximab-induced immunodysregulatory ileocolitis in a patient with follicular lymphoma
-
Blombery P, Prince HM, Levinson M, et al. Rituximab-induced immunodysregulatory ileocolitis in a patient with follicular lymphoma. J Clin Oncol 2011;29:e110-12.
-
(2011)
J Clin Oncol
, vol.29
-
-
Blombery, P.1
Prince, H.M.2
Levinson, M.3
-
91
-
-
42549142171
-
Ulcerative colitis following B lymphocyte depletion with rituximab in a patient with Graves' disease
-
DOI 10.1136/gut.2007.138305
-
El Fassi D, Nielsen CH, Kjeldsen J, et al. Ulcerative colitis following B lymphocyte depletion with rituximab in a patient with Grave's disease. Gut 2008;57:714-15. (Pubitemid 351579988)
-
(2008)
Gut
, vol.57
, Issue.5
, pp. 714-715
-
-
El, F.D.1
Nielsen, C.H.2
Kjeldsen, J.3
Clemmensen, O.4
Hegedus, L.5
-
92
-
-
77954362764
-
Severe ulcerative colitis after rituximab therapy
-
Ardelean DS, Gonska T, Wires S, et al. Severe ulcerative colitis after rituximab therapy. Pediatrics 2010;126:e243-6.
-
(2010)
Pediatrics
, vol.126
-
-
Ardelean, D.S.1
Gonska, T.2
Wires, S.3
-
93
-
-
36749004359
-
Exacerbation of ulcerative colitis after rituximab salvage therapy
-
DOI 10.1002/ibd.20215
-
Goetz M, Atreya R, Ghalibafian M, et al. Exacerbation of ulcerative colitis after rituximab salvage therapy. Inflamm Bowel Dis 2007;13:1365-8. (Pubitemid 350206846)
-
(2007)
Inflammatory Bowel Diseases
, vol.13
, Issue.11
, pp. 1365-1368
-
-
Goetz, M.1
Atreya, R.2
Ghalibafian, M.3
Galle, P.R.4
Neurath, M.F.5
-
94
-
-
79955572862
-
DDW 2010 649: A randomized placebo-controlled trial of abatacept for moderately-to-severely active Crohn's disease (CD)
-
Hanauer SB, Sandborn WJ, Sands BE, et al. DDW 2010 649: a randomized placebo-controlled trial of abatacept for moderately-to-severely active Crohn's disease (CD). Gastroenterology 2010;138(Suppl 1):S-86.
-
(2010)
Gastroenterology
, vol.138
, Issue.SUPPL. 1
-
-
Hanauer, S.B.1
Sandborn, W.J.2
Sands, B.E.3
-
95
-
-
84860599481
-
A study of abatacept in patients with active ulcerative colitis
-
Abstract. accessed Jul 2011
-
Sandborn WJ, et al. A study of abatacept in patients with active ulcerative colitis. American College of Gastroenterology Annual Meeting; 2009;Abstract. http://clinicaltrial.gov (accessed Jul 2011)
-
American College of Gastroenterology Annual Meeting; 2009
-
-
Sandborn, W.J.1
-
96
-
-
0035978651
-
Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease
-
DOI 10.1038/35079107
-
Hugot J-P, Chamaillard M, Zouali H, et al. Associations of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001;411:599-603. (Pubitemid 32531408)
-
(2001)
Nature
, vol.411
, Issue.6837
, pp. 599-603
-
-
Hugot, J.-P.1
Chamaillard, M.2
Zouali, H.3
Lesage, S.4
Cezard, J.-P.5
Belaiche, J.6
Almer, S.7
Tysk, C.8
O'morain, C.A.9
Gassull, M.10
Binder, V.11
Finkel, Y.12
Cortot, A.13
Modigliani, R.14
Laurent-Puig, P.15
Gower-Rousseau, C.16
Macry, J.17
Colombel, J.-F.18
Sahbatou, M.19
Thomas, G.20
more..
-
97
-
-
0035978533
-
A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease
-
DOI 10.1038/35079114
-
Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001;411:603-6. (Pubitemid 32531409)
-
(2001)
Nature
, vol.411
, Issue.6837
, pp. 603-606
-
-
Ogura, Y.1
Bonen, D.K.2
Inohara, N.3
Nicolae, D.L.4
Chen, F.F.5
Ramos, R.6
Britton, H.7
Moran, T.8
Karaliuskas, R.9
Duerr, R.H.10
Achkar, J.-P.11
Brant, S.R.12
Bayless, T.M.13
Kirschner, B.S.14
Hanauer, S.B.15
Nuez, G.16
Cho, J.H.17
-
98
-
-
29144483937
-
Reduced Paneth cell alpha-defensins in ileal Crohn's disease
-
DOI 10.1073/pnas.0505256102
-
Wehkamp J, Salzman NH, Porter E, et al. Reduced Paneth cell alpha-defensins in ileal Crohn's disease. Proc Natl Acad Sci U S A 2005;102:18129-34. (Pubitemid 41798513)
-
(2005)
Proceedings of the National Academy of Sciences of the United States of America
, vol.102
, Issue.50
, pp. 18129-18134
-
-
Wehkamp, J.1
Salzman, N.H.2
Porter, E.3
Nuding, S.4
Weichenthal, M.5
Petras, R.E.6
Shen, B.7
Schaeffeler, E.8
Schwab, M.9
Linzmeier, R.10
Feathers, R.W.11
Chu, H.12
Lima Jr., H.13
Fellermann, K.14
Ganz, T.15
Stange, E.F.16
Bevins, C.L.17
-
99
-
-
0347987896
-
An open-label pilot study of granulocyte colony-stimulating factor for the treatment of severe endoscopic postoperative recurrence in Crohn's disease
-
DOI 10.1159/000074517
-
Dejaco C, Lichtenberger C, Miehsler W, et al. An open-label pilot study of granulocyte colony-stimulating factor for the treatment of severe endoscopic postoperative recurrence in Crohn's disease. Digestion 2003;68:63-70. (Pubitemid 38056704)
-
(2003)
Digestion
, vol.68
, Issue.2-3
, pp. 63-70
-
-
Dejaco, C.1
Lichtenberger, C.2
Miehsler, W.3
Oberhuber, G.4
Herbst, F.5
Vogelsang, H.6
Gangl, A.7
Reinisch, W.8
-
100
-
-
14644404938
-
An open-labelled study of granulocyte colony-stimulating factor in the treatment of active Crohn's disease
-
DOI 10.1111/j.1365-2036.2005.02287.x
-
Korzenik JR, Dieckgraefe BK. An open-labelled study of granulocyte colony-stimulating factor in the treatment of active Crohn's disease. Aliment Pharmacol Ther 2005;21:391-400. (Pubitemid 40313941)
-
(2005)
Alimentary Pharmacology and Therapeutics
, vol.21
, Issue.4
, pp. 391-400
-
-
Korzenik, J.R.1
Dieckgraefe, B.K.2
-
101
-
-
0037048904
-
Treatment of active Crohn's disease with recombinant human granulocyte-macrophage colony-stimulating factor
-
DOI 10.1016/S0140-6736(02)11437-1
-
Dieckgraefe BK, Korzenik JR. Treatment of active Crohn's disease with recombinant human granulocyteemacrophage colony-stimulating factor. Lancet 2002;360:1478-80. (Pubitemid 35356328)
-
(2002)
Lancet
, vol.360
, Issue.9344
, pp. 1478-1480
-
-
Dieckgraefe, B.K.1
Korzenik, J.R.2
-
102
-
-
19444363154
-
Sargramostim for active Crohn's disease
-
DOI 10.1056/NEJMoa041109
-
Korzenik JR, Dieckgraefe BK, Valentine JF, et al. Sargramostim for active Crohn's disease. N Engl J Med 2005;352:2193-201. (Pubitemid 40727086)
-
(2005)
New England Journal of Medicine
, vol.352
, Issue.21
, pp. 2193-2201
-
-
Korzenik, J.R.1
Dieckgraefe, B.K.2
Valentine, J.F.3
Hausman, D.F.4
Gilbert, M.J.5
-
103
-
-
70349321253
-
Steroid-sparing properties of sargramostim in patients with corticosteroiddependent Crohn's disease: A randomised, double-blind, placebocontrolled, phase 2 study
-
Valentine JF, Fedorak R, Feagan BG, et al. Steroid-sparing properties of sargramostim in patients with corticosteroiddependent Crohn's disease: a randomised, double-blind, placebocontrolled, phase 2 study. Gut 2009;58:1354-62.
-
(2009)
Gut
, vol.58
, pp. 1354-1362
-
-
Valentine, J.F.1
Fedorak, R.2
Feagan, B.G.3
-
104
-
-
77953718243
-
Phase I trial of sargramostim in pediatric Crohn's disease
-
Kelsen JR, Rosh J, Heyman M, et al. Phase I trial of sargramostim in pediatric Crohn's disease. Inflamm Bowel Dis 2010;16:1203-8.
-
(2010)
Inflamm Bowel Dis
, vol.16
, pp. 1203-1208
-
-
Kelsen, J.R.1
Rosh, J.2
Heyman, M.3
-
105
-
-
34848858527
-
Efficacy and safety of sargramostim in moderate to severe Crohn's disease: Results of NOVEL 4, a Phase II multicenter study
-
Feagan BG, Anderson FH, Radford-Smith GL, et al. Efficacy and safety of sargramostim in moderate to severe Crohn's disease: results of NOVEL 4, a Phase II multicenter study. Digestive Disease Week 2007;132:A737.
-
(2007)
Digestive Disease Week
, vol.132
-
-
Feagan, B.G.1
Anderson, F.H.2
Radford-Smith, G.L.3
-
106
-
-
0027407109
-
Endothelial-leukocyte adhesion molecules
-
Bevilacqua MP. Endothelial-leukocyte adhesion molecules. Annu Rev Immunol 1993;11:767-804. (Pubitemid 23115023)
-
(1993)
Annual Review of Immunology
, vol.11
, pp. 767-804
-
-
Bevilacqua, M.P.1
-
107
-
-
0026770377
-
Integrins: Versatility, modulation, and signaling in cell adhesion
-
Hynes RO. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 1992;69:11-25.
-
(1992)
Cell
, vol.69
, pp. 11-25
-
-
Hynes, R.O.1
-
108
-
-
53849097306
-
Nonimmune cells in inflammatory bowel disease: From victim to villain
-
Danese S. Nonimmune cells in inflammatory bowel disease: from victim to villain. Trends Immunol 2008;29:555-64.
-
(2008)
Trends Immunol
, vol.29
, pp. 555-564
-
-
Danese, S.1
-
109
-
-
77954179519
-
Anti-adhesion molecule therapy for inflammatory bowel disease
-
Ghosh S, Panaccione R. Anti-adhesion molecule therapy for inflammatory bowel disease. Therap Adv Gastroenterol 2010;3:239-58.
-
(2010)
Therap Adv Gastroenterol
, vol.3
, pp. 239-258
-
-
Ghosh, S.1
Panaccione, R.2
-
110
-
-
0033231492
-
Human G protein-coupled receptor GPR-9-6/CC chemokine receptor 9 is selectively expressed on intestinal homing T lymphocytes, mucosal lymphocytes, and thymocytes and is required for thymus-expressed chemokine-mediated chemotaxis
-
Zabel BA, Agace WW, Campbell JJ, et al. Human G protein-coupled receptor GPR-9-6/CC chemokine receptor 9 is selectively expressed on intestinal homing T lymphocytes, mucosal lymphocytes, and thymocytes and is required for thymus-expressed chemokine-mediated chemotaxis. J Exp Med 1999;190:1241-56.
-
(1999)
J Exp Med
, vol.190
, pp. 1241-1256
-
-
Zabel, B.A.1
Agace, W.W.2
Campbell, J.J.3
-
111
-
-
84860582480
-
-
accessed Jul 2011
-
Food and Drug Administration. Approval of Natalizumab for Use in Crohn's disease. 2008. http://www.accessdata.fda.gov/drugsatfda-docs/appletter/2008/ 125104s0033ltr.pdf (accessed Jul 2011).
-
(2008)
Approval of Natalizumab for Use in Crohn's Disease
-
-
-
112
-
-
0034903450
-
A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease
-
Gordon FH, Lai CW, Hamilton MI, et al. A randomized placebocontrolled trial of humanized monoclonal antibody to alpha4 integrin in active Crohn's disease. Gastroenterology 2001;121:268-74. (Pubitemid 32729374)
-
(2001)
Gastroenterology
, vol.121
, Issue.2
, pp. 268-274
-
-
Gordon, F.H.1
Lai, C.W.Y.2
Hamilton, M.I.3
Allison, M.C.4
Srivastava, E.D.5
Fouweather, M.G.6
Donoghue, S.7
Greenlees, C.8
Subhani, J.9
Amlot, P.L.10
Pounder, R.E.11
-
113
-
-
34247884424
-
Natalizumab for the Treatment of Active Crohn's Disease: Results of the ENCORE Trial
-
DOI 10.1053/j.gastro.2007.03.024, PII S0016508507005380
-
Targan SR, Feagan BG, Fedorak RN, et al. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE trial. Gastroenterology 2007;132:1672-83. (Pubitemid 46695722)
-
(2007)
Gastroenterology
, vol.132
, Issue.5
, pp. 1672-1683
-
-
Targan, S.R.1
Feagan, B.G.2
Fedorak, R.N.3
Lashner, B.A.4
Panaccione, R.5
Present, D.H.6
Spehlmann, M.E.7
Rutgeerts, P.J.8
Tulassay, Z.9
Volfova, M.10
Wolf, D.C.11
Hernandez, C.12
Bornstein, J.13
Sandborn, W.J.14
-
114
-
-
79953801792
-
Efficacy of biological therapies in inflammatory bowel disease: Systematic review and meta-analysis
-
Ford AC, Sandborn WJ, Khan KJ, et al. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 2011;106:644-59.
-
(2011)
Am J Gastroenterol
, vol.106
, pp. 644-659
-
-
Ford, A.C.1
Sandborn, W.J.2
Khan, K.J.3
-
115
-
-
22844445230
-
Progressive multifocal leukoencephalopathy in a patient treated with natalizumab
-
DOI 10.1056/NEJMoa051847
-
Langer-Gould A, Atlas SW, Green AJ, et al. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005;353:375-81. (Pubitemid 41132342)
-
(2005)
New England Journal of Medicine
, vol.353
, Issue.4
, pp. 375-381
-
-
Langer-Gould, A.1
Atlas, S.W.2
Green, A.J.3
Bollen, A.W.4
Pelletier, D.5
-
116
-
-
22844445587
-
Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease
-
DOI 10.1056/NEJMoa051586
-
Van Assche G, Van Ranst M, Sciot R, et al. Progressive mutlifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 2005;353:362-8. (Pubitemid 41132340)
-
(2005)
New England Journal of Medicine
, vol.353
, Issue.4
, pp. 362-368
-
-
Van Assche, G.1
Van Ranst, M.2
Sciot, R.3
Dubois, B.4
Vermeire, S.5
Noman, M.6
Verbeeck, J.7
Geboes, K.8
Robberecht, W.9
Rutgeerts, P.10
-
117
-
-
33644605483
-
Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy
-
Yousry TA, Habil M, Major EO, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 2006;354:924-33.
-
(2006)
N Engl J Med
, vol.354
, pp. 924-933
-
-
Yousry, T.A.1
Habil, M.2
Major, E.O.3
-
118
-
-
79957449040
-
Clinical outcomes of natalizumab-associated progressive multifocal leukpencephalopathy
-
Vermersch P, Kappos L, Gold R, et al. Clinical outcomes of natalizumab-associated progressive multifocal leukpencephalopathy. Neurology 2011;76:1697-704.
-
(2011)
Neurology
, vol.76
, pp. 1697-1704
-
-
Vermersch, P.1
Kappos, L.2
Gold, R.3
-
119
-
-
20444469332
-
7 integrin
-
DOI 10.1056/NEJMoa042982
-
Feagan BG, Greenberg GR, Wild G, et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med 2005;352:2499-507. (Pubitemid 41007865)
-
(2005)
New England Journal of Medicine
, vol.352
, Issue.24
, pp. 2499-2507
-
-
Feagan, B.G.1
Greenberg, G.R.2
Wild, G.3
Fedorak, R.N.4
Pare, P.5
McDonald, J.W.D.6
Dube, R.7
Cohen, A.8
Steinhart, A.H.9
Landau, S.10
Aguzzi, R.A.11
Fox, I.H.12
Vandervoort, M.K.13
-
120
-
-
57249089077
-
Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin
-
Feagan BG, Greenberg GR, Wild G, et al. Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin. Clin Gastroenterol Hepatol 2008;6:1370-7.
-
(2008)
Clin Gastroenterol Hepatol
, vol.6
, pp. 1370-1377
-
-
Feagan, B.G.1
Greenberg, G.R.2
Wild, G.3
-
121
-
-
84927975259
-
The gastrointestinal-selective biologic vedolizumab does not impair immune surveillance of the central nervous system in non-human primates
-
Fedyk ER, Csizmadia V, Chyi Shyu W, et al. The gastrointestinal-selective biologic vedolizumab does not impair immune surveillance of the central nervous system in non-human primates. JCC 2011;5:2.
-
(2011)
JCC
, vol.5
, pp. 2
-
-
Fedyk, E.R.1
Csizmadia, V.2
Chyi Shyu, W.3
-
122
-
-
0032867984
-
ISIS 2302, an antisense inhibitor of intercellular adhesion molecule 1
-
DOI 10.1517/13543784.8.9.1417
-
Shanahan WR Jr. ISIS 2302, an antisense inhibitor of intercellular adhesion molecule 1. Expert Opin Investig Drugs 1999;8:1417-29. (Pubitemid 29417625)
-
(1999)
Expert Opinion on Investigational Drugs
, vol.8
, Issue.9
, pp. 1417-1429
-
-
Shanahan Jr., W.R.1
-
123
-
-
0031782392
-
A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease
-
DOI 10.1016/S0016-5085(98)70418-4
-
Yacyshyn BR, Bowen-Yacyshyn MB, Jewell L, et al. A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease. Gastroenterology 1998;114:1133-42. (Pubitemid 28243898)
-
(1998)
Gastroenterology
, vol.114
, Issue.6
, pp. 1133-1142
-
-
Yacyshyn, B.R.1
Bowen-Yacyshyn, M.B.2
Jewell, L.3
Tami, J.A.4
Bennett, C.F.5
Kisner, D.L.6
Shanahan Jr., W.R.7
-
124
-
-
0035045185
-
Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn's disease
-
Schreiber S, Nikolaus S, Malchow HA, et al. Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn's disease. Gastroenterology 2001;120:1339-46. (Pubitemid 32322307)
-
(2001)
Gastroenterology
, vol.120
, Issue.6
, pp. 1339-1346
-
-
Schreiber, S.1
Nikolaus, S.2
Malchow, H.3
Kruis, W.4
Lochs, H.5
Raedler, A.6
Hahn, E.G.7
Krummenerl, T.8
Steinmann, G.9
-
125
-
-
0036288638
-
Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease
-
DOI 10.1136/gut.51.1.30
-
Yacyshyn BR, Chey WY, Goff J, et al. Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease. Gut 2002;51:30-6. (Pubitemid 34717740)
-
(2002)
Gut
, vol.51
, Issue.1
, pp. 30-36
-
-
Yacyshyn, B.R.1
Chey, W.Y.2
Goff, J.3
Salzberg, B.4
Baerg, R.5
Buchman, A.L.6
Tami, J.7
Yu, R.8
Gibiansky, E.9
Shanahan, W.R.10
-
126
-
-
33846804162
-
A Randomized, Double-Masked, Placebo-Controlled Study of Alicaforsen, an Antisense Inhibitor of Intercellular Adhesion Molecule 1, for the Treatment of Subjects With Active Crohn's Disease
-
DOI 10.1016/j.cgh.2006.11.001, PII S1542356506011451
-
Yacyshyn BR, Chey WY, Wedel MK, et al. A randomized, double-masked, placebo-controlled study of alicaforsen, an antisense inhibitor of intercellular adhesion molecule 1, for the treatment of subjects with active Crohn's disease. Clin Gastroenterol Hepatol 2007;5:215-20. (Pubitemid 46216935)
-
(2007)
Clinical Gastroenterology and Hepatology
, vol.5
, Issue.2
, pp. 215-220
-
-
Yacyshyn, B.1
Chey, W.Y.2
Wedel, M.K.3
Yu, R.Z.4
Paul, D.5
Chuang, E.6
-
127
-
-
33646237136
-
Bioavailability and therapeutic activity of alicaforsen (ISIS 2302) administered as a rectal retention enema to subjects with active ulcerative colitis
-
Miner PB, Geary RS, Matson J, et al. Bioavailability and therapeutic activity of alicaforsen (ISIS 2302) administered as a rectal retention enema to subjects with active ulcerative colitis. Aliment Pharmacol Ther 2006;23:1427-34.
-
(2006)
Aliment Pharmacol Ther
, vol.23
, pp. 1427-1434
-
-
Miner, P.B.1
Geary, R.S.2
Matson, J.3
-
128
-
-
33646271377
-
A phase II dose ranging, double-blind, placebo-controlled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate left-sided ulcerative colitis
-
van Deventer SJ, Wedel MK, Baker BF, et al. A phase II dose ranging, double-blind, placebo-controlled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate left-sided ulcerative colitis. Aliment Pharmacol Ther 2006;23:1415-25.
-
(2006)
Aliment Pharmacol Ther
, vol.23
, pp. 1415-1425
-
-
Van Deventer, S.J.1
Wedel, M.K.2
Baker, B.F.3
-
129
-
-
77957244016
-
Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease
-
Walters MJ, Wang Y, Lai N, et al. Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease. J Pharmacol Exp Ther 2010;335:61-9.
-
(2010)
J Pharmacol Exp Ther
, vol.335
, pp. 61-69
-
-
Walters, M.J.1
Wang, Y.2
Lai, N.3
-
130
-
-
84865435185
-
Chemokine receptor antagonist CXC282-B (Traficet-En) maintained remission of Crohn's disease in PROTECT-1 study
-
Keshav S, Johnson D, Schall T, et al. Chemokine receptor antagonist CXC282-B (Traficet-En) maintained remission of Crohn's disease in PROTECT-1 study. Digestive Disease Week 2010:A647.
-
(2010)
Digestive Disease Week
-
-
Keshav, S.1
Johnson, D.2
Schall, T.3
-
132
-
-
79960336916
-
The mucosal addressin cell adhesion molecule antibody PF-00547,659 in ulcerative colitis: A randomised study
-
Vermeire S, Ghosh S, Panes J, et al. The mucosal addressin cell adhesion molecule antibody PF-00547,659 in ulcerative colitis: a randomised study. Gut 2011;60:1068-75.
-
(2011)
Gut
, vol.60
, pp. 1068-1075
-
-
Vermeire, S.1
Ghosh, S.2
Panes, J.3
-
133
-
-
79955562875
-
Oral alpha-4 integrin inhibitor (AJM300) in patients with active Crohn's disease: A randomized, double-blind, placebo-controlled trial
-
Takazoe M, Watanabe M, Kawaguchi T, et al. Oral alpha-4 integrin inhibitor (AJM300) in patients with active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Digestive Disease Week 2009;136:S1066.
-
(2009)
Digestive Disease Week
, vol.136
-
-
Takazoe, M.1
Watanabe, M.2
Kawaguchi, T.3
-
134
-
-
84860558067
-
A phase I study of rHuMab beta7 in moderate to severe ulcerative colitis
-
Rutgeerts P, Fedorak R, Hommes D, et al. A phase I study of rHuMab beta7 in moderate to severe ulcerative colitis. Digestive Disease Week 2011:A748.
-
(2011)
Digestive Disease Week
-
-
Rutgeerts, P.1
Fedorak, R.2
Hommes, D.3
-
135
-
-
78650653452
-
Autologous nonmyeloablative hematopoietic stem cell transplantation in patients with severe anti-TNF refractory Crohn disease: Long-term follow-up
-
Burt RK, Craig RM, Milanetti F, et al. Autologous nonmyeloablative hematopoietic stem cell transplantation in patients with severe anti-TNF refractory Crohn disease: long-term follow-up. Blood 2010;116:6123-32.
-
(2010)
Blood
, vol.116
, pp. 6123-6132
-
-
Burt, R.K.1
Craig, R.M.2
Milanetti, F.3
-
136
-
-
78649895490
-
Autlogous bone-marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn's disease: Results of a phase I study
-
Duijvestein M, Vos AC, Roelofs H, et al. Autlogous bone-marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn's disease: results of a phase I study. Gut 2010;59:1662-9.
-
(2010)
Gut
, vol.59
, pp. 1662-1669
-
-
Duijvestein, M.1
Vos, A.C.2
Roelofs, H.3
-
137
-
-
79955853222
-
Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn's disease
-
Ciccocioppo R, Bernardo ME, Sgarella A, et al. Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn's disease. Gut 2011;60:788-98.
-
(2011)
Gut
, vol.60
, pp. 788-798
-
-
Ciccocioppo, R.1
Bernardo, M.E.2
Sgarella, A.3
-
138
-
-
64049104052
-
Expanded adipose-derived stem cells for the treatment of complex perianal fistula: A phase II clinical trial
-
Garcia-Olmo D, Herreros D, Pascual I, et al. Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial. Dis Colon Rectum 2009;52:79-86.
-
(2009)
Dis Colon Rectum
, vol.52
, pp. 79-86
-
-
Garcia-Olmo, D.1
Herreros, D.2
Pascual, I.3
-
139
-
-
36749038197
-
Mucosal T-cell immunoregulation varies in early and late inflammatory bowel disease
-
DOI 10.1136/gut.2006.116467
-
Kugathasan S, Saubermann LJ, Smith L, et al. Mucosal T-cell immunoregulation varies in early and late inflammatory bowel disease. Gut 2007;56:1696-705. (Pubitemid 350206296)
-
(2007)
Gut
, vol.56
, Issue.12
, pp. 1696-1705
-
-
Kugathasan, S.1
Saubermann, L.J.2
Smith, L.3
Kou, D.4
Itoh, J.5
Binion, D.G.6
Levine, A.D.7
Blumberg, R.S.8
Fiocchi, C.9
-
140
-
-
77950988234
-
Infliximab, azathioprine, or combination therapy for Crohn's disease
-
Colombel J-F, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010;362:1383-95.
-
(2010)
N Engl J Med
, vol.362
, pp. 1383-1395
-
-
Colombel, J.-F.1
Sandborn, W.J.2
Reinisch, W.3
-
141
-
-
79952783670
-
Does anti-TNF therapy reduce the requirement for surgery in ulcerative colitis? A systematic review
-
Filippi J, Allen PB, Hebuterne X, et al. Does anti-TNF therapy reduce the requirement for surgery in ulcerative colitis? A systematic review. Curr Drug Targets 2011;12:1440-7.
-
(2011)
Curr Drug Targets
, vol.12
, pp. 1440-1447
-
-
Filippi, J.1
Allen, P.B.2
Hebuterne, X.3
-
142
-
-
77149169736
-
Early Crohn disease: A proposed definition for use in disease-modification trials
-
Peyrin-Biroulet L, Loftus EV, Colombel J-F, et al. Early Crohn disease: a proposed definition for use in disease-modification trials. Gut 2010;59:141-7.
-
(2010)
Gut
, vol.59
, pp. 141-147
-
-
Peyrin-Biroulet, L.1
Loftus, E.V.2
Colombel, J.-F.3
-
143
-
-
84855216805
-
Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health
-
Peyrin-Biroulet L, Cieza A, Sandborn WJ, et al. Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health. Gut 2012;61(2): 241-47.
-
(2012)
Gut
, vol.61
, Issue.2
, pp. 241-247
-
-
Peyrin-Biroulet, L.1
Cieza, A.2
Sandborn, W.J.3
-
144
-
-
79955844087
-
Development of the Crohn's disease digestive damage score, the Lemann score
-
Pariente B, Cosnes J, Danese S, et al. Development of the Crohn's disease digestive damage score, the Lemann score. Inflamm Bowel Dis 2011;17:1415-22.
-
(2011)
Inflamm Bowel Dis
, vol.17
, pp. 1415-1422
-
-
Pariente, B.1
Cosnes, J.2
Danese, S.3
|